Low-Dose Rivaroxaban Plus Aspirin in Older Patients W Undergoing Acute Limb Revascularization: Insights Fro

European Heart Journal

42, 4040-4048

DOI: 10.1093/eurheartj/ehab408

Citation Report

#	Article	IF	Citations
1	Low-Dose Rivaroxaban Plus Aspirin for Elderly Patients With Symptomatic Peripheral Artery Disease: Is It Worth the Bleeding Risk?. European Heart Journal, 2021, 42, 4049-4052.	14.7	6
2	Thrombosis in Peripheral Artery Disease and Thrombotic Thrombocytopenia After Adenoviral COVID-19 Vaccination. European Heart Journal, 2021, 42, 3995-3999.	14.7	1
3	Risk Factors for Stroke in Penetrating Carotid Trauma—An Analysis From the PROOVIT Registry. Journal of Trauma and Acute Care Surgery, 2022, 92, 717.	3.7	14
4	A Comprehensive Update on Cardiovascular Surgery: Challenges and Opportunities. European Heart Journal, 2021, 43, 1-5.	14.7	8
5	The Challenge of Cardiovascular Prevention in the Elderly: Importance of Randomized Clinical Trials. European Heart Journal, 2022, 43, 1997-2000.	14.7	1
6	Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. JAMA Network Open, 2022, 5, e2215580-e2215580.	10.2	19
7	Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. Journal of the Society for Cardiovascular Angiography & Interventions, 2022, 1, 100513.	2.3	25
8	Acetylsalicylic Acid–Primus Inter Pares in Pharmacology. Molecules, 2022, 27, 8412.	5.4	37
9	Acute, Periprocedural and Longterm Antithrombotic Therapy in Older Adults: 2022 Update by the ESC Working Group on Thrombosis. European Heart Journal, 2023, 44, 262-279.	14.7	58
10	The Key Role of Trials in Cardiovascular Medicine: Challenges and Opportunities. European Heart Journal, 2023, 44, 905-908.	14.7	0
11	Low Dose Rivaroxaban for the Management of Atherosclerotic Cardiovascular Disease. Journal of Thrombosis and Thrombolysis, 2023, 56, 91-102.	2.2	9
12	Oral Factor Xa Inhibitor Underutilization Following Lower Extremity Peripheral Vascular Intervention. Journal of Vascular Surgery, 2023, 78, 498-505.e1.	3.4	8
13	Sex and Racial Disparities in Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 2099-2114.	7.9	26
14	A Systematic Review and Meta-Analysis of the Morbidity of Efficacy Endpoints and Bleeding Events in Elderly and Young Patients Treated With the Same Dose Rivaroxaban. Annals of Hematology, 2024, 103, 1-11.	2.1	3
15	Selection Criteria for Anticoagulants: Survey of Japanese Cardiologists Based on Their Daily Clinical Practice: The Selection DOAC Study. Current Medical Research and Opinion, 2024, 40, 1077-1082.	2.9	0
16	Calcium and Atherosclerosis in Lower Extremities. , 2024, .		0
17	Antithrombotic Therapy in Patients Undergoing Peripheral Artery Interventions. Interventional Cardiology Clinics, 2024, 13, 553-559.	1.1	1
18	Rivaroxaban to Reduce the Risk of Major Cardiovascular Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease: A Narrative Review. Expert Opinion on Drug Safety, 2025, 24, 261-271.	3.2	7

#	Article	IF	Citations
19	Current Antithrombotic Prescribing Habits for Extended Secondary Prevention in Patients With Peripheral Artery Disease and Unprovoked Venous Thromboembolism: A Survey Among Specialists in Angiology and Vascular Surgery. Journal of Clinical Medicine, 2025, 14, 5157.	3.8	4
20	Vascular Aging as a Driver of Thrombosis in Older Adults: From Mechanisms to Gerotherapeutics. , 2025, 2, 202513.		0
21	Épidémiologie descriptive & facteurs pronostiques de l'artériopathie oblitérante des membres inférieurs dans les populations négligées. , 0, .		0
22	Peripheral Artery Disease Treatment: Scoping Review With ❄SAIMSARA. , 2026, .		0
23	Efficacy and Safety of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Peripheral Arterial Disease: A Systematic Review and Meta-Analysis. Annals of Medicine and Surgery, 2026, 88, 4437-4447.	1.7	0